Drug or treatment

Anifrolumab clinical trials

• 19Clinical trials
• 1New in 30 days
• 49Countries

Newest trials

All recruiting trials (19)

• Effects of anifrolumab on arterial inflammation in SLE patients

  This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.

  Recruiting University of Cambridge · Cambridge, Cambridgeshire · NCT07913919

• Anifrolumab in Chinese patients with active moderate-to-severe SLE

  This study tests whether adding anifrolumab to standard care helps Chinese adults with active moderate-to-severe SLE achieve remission and reduces glucocorticoid use.

  Recruiting at 25 sites Phase 3 AstraZeneca · Beijing and 73 other locations · NCT07751848

• Keeping you on anifrolumab after a positive finish with your prior study

  This study lets people who finished a prior anifrolumab trial and still benefit continue receiving the medicine to see if it stays safe and tolerable for them.

  Recruiting at 4 sites Phase 3 AstraZeneca · Phoenix, Arizona and 165 other locations · NCT07691970

• Subcutaneous anifrolumab in children with systemic lupus erythematosus

  This study tests whether subcutaneous anifrolumab is safe and how it behaves in the body for kids with moderate to severe SLE already on standard care.

  Recruiting at 2 sites Phase 2 AstraZeneca · Nedlands and 38 other locations · NCT07630714

• LUPKYNIS in combination with belimumab, obinutuzumab, or anifrolumab for lupus nephritis

  This trial tests whether adding LUPKYNIS to other biologics (belimumab, obinutuzumab, or anifrolumab) plus a mycophenolic acid analog and a steroid can rapidly improve kidney health in adults with biopsy-proven lupus nephritis.

  Recruiting at 27 sites Phase 4 Aurinia Pharmaceuticals Inc. · La Mesa, California and 26 other locations · NCT07611214

• Anifrolumab for adults with primary antiphospholipid syndrome

  This phase II pilot tests whether weekly subcutaneous anifrolumab is safe and tolerable in adults with primary antiphospholipid syndrome while they continue their standard care.

  Recruiting Phase 2 National and Kapodistrian University of Athens · Athens, Greece · NCT07584083

• Weekly subcutaneous anifrolumab added to antimalarial for people with lupus who are immunosuppressant- and biologic-naïve

  This trial tests whether once-weekly 120 mg subcutaneous anifrolumab plus antimalarial (with or without steroids) helps adults with lupus who have not used immunosuppressants or biologics reach remission and come off long-term steroids.

  Recruiting at 50 sites Phase 3 AstraZeneca · Anniston, Alabama and 107 other locations · NCT07430306

• Disease activity and quality of life in adults with SLE starting subcutaneous anifrolumab

  This project will try to see how subcutaneous anifrolumab works for adults with lupus by collecting clinical measurements and patient-reported outcomes in routine care.

  Recruiting at 21 sites AstraZeneca · Altenburg and 20 other locations · NCT07424261

• Anifrolumab to achieve LLDAS5 in people with systemic lupus erythematosus

  This study tests whether anifrolumab helps people with systemic lupus erythematosus reach and keep low disease activity while staying on 5 mg/day or less of corticosteroids.

  Recruiting at 14 sites AstraZeneca · Monserrato, CA and 21 other locations · NCT07330245

• Real-world use of anifrolumab for active systemic lupus erythematosus

  This project will see if anifrolumab helps adults with active systemic lupus erythematosus when given in routine clinical care.

  Recruiting University of Pisa · Pisa · NCT07215754

• Anifrolumab Pregnancy Study in women with lupus

  This study looks at pregnancy outcomes in women with moderate to severe SLE who took anifrolumab during pregnancy and compares them to similar women who did not take the drug.

  Recruiting AstraZeneca · Cary, North Carolina · NCT07049653

• Anifrolumab and risk of cancers and serious infections in SLE

  This project will see if adults with moderate-to-severe SLE who start anifrolumab have different rates of cancers and serious infections than similar patients receiving standard care.

  Recruiting at 4 sites AstraZeneca · Copenhagen and 3 other locations · NCT07000110

• Monitoring pregnancy and infant outcomes after anifrolumab exposure

  This program collects health information to see if exposure to the lupus medicine anifrolumab affects pregnant people or their babies.

  Recruiting AstraZeneca · Södertälje · NCT06795893

• Registry to investigate maternal and infant outcomes in users of anifrolumab during pregnancy

  This study is looking to see how using the drug anifrolumab during pregnancy affects mothers and their babies, specifically for those with systemic lupus erythematosus.

  Recruiting AstraZeneca · Wilmington, North Carolina · NCT06659029

• Investigating outcomes in mothers and infants using Anifrolumab

  This study is testing whether Anifrolumab, a medication for lupus, shows up in breast milk and affects breastfeeding mothers and their infants.

  Recruiting Phase 4 AstraZeneca · Las Vegas, Nevada · NCT06594068

• Evaluating Anifrolumab for Treating Polymyositis and Dermatomyositis

  This study is testing if a new drug called anifrolumab can help adults with polymyositis and dermatomyositis feel better compared to a placebo while they continue their usual treatments.

  Recruiting at 180 sites Phase 3 AstraZeneca · Phoenix, Arizona and 236 other locations · NCT06455449

• Evaluating lupus outcomes after using Anifrolumab in real-world settings

  This study is testing how well Anifrolumab works for people with lupus when added to their usual treatment, focusing on improvements in their symptoms over a year.

  Recruiting at 5 sites AstraZeneca · Buenos Aires and 31 other locations · NCT06314282

• Intravenous anifrolumab for children with moderate to severe systemic lupus erythematosus

  This study will try intravenous anifrolumab in children with moderate to severe SLE to see if it is safe and helps control their disease while they remain on standard treatment.

  Recruiting at 84 sites Phase 3 AstraZeneca · Phoenix, Arizona and 102 other locations · NCT05835310

• Anifrolumab's effect on blood vessel health in lupus patients

  This study is testing if the drug anifrolumab can help improve blood vessel health and reduce inflammation in people with lupus.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05440422

Quick answers

How many clinical trials of Anifrolumab are recruiting right now?

19, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 49 countries. The most sites are in United States (9 trials), Germany (6 trials), Italy (6 trials), France (5 trials), Spain (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 5, Phase 2: 3, Phase 4: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →